Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: To Shareholders

Seems to me that the main impediment to new shareholder investment is, and has always been shareholder enlightenment. TPL's plan all along has been to gain control of the MMP from Moore, and eventually us, through weakening our finanical position. TPL has played our BOD into a corner along with Moore. If we negotiate an agreement with them they will just eventually do it again. It is the nature of the beast. Been proven past and present. Hopefully our BOD unlike TPL can at least learn from their mistakes. JMO.

Share
New Message
Please login to post a reply